The Tucson, Arizona-based company previously raised $20 million through a public offering of its shares and a purchase deal with certain investors.
Medley Genomics' software, called HotNet2, assesses tumor genomic heterogeneity from large-scale sequencing datasets across patient cohorts.
The company incurred a net loss of $5.2 million, or $.10 per share, slightly exceeding the $.09 per share loss that analysts had predicted on average.
The firm will use funds from the round, led by the Midlands Engine Investment Fund, to develop its optical point-of-care diagnostic testing platform.
By uncovering mismatches between Y chromosomes and genealogies, researchers estimated historical rates of extra-pair paternity in Western Europe.
Genotypes for more than 12,000 individuals from the Americas revealed contributions from European colonization, the Atlantic slave trade, and other migrations.
The partners will evaluate circulating tumor cell-based biomarker panels as potential new tests for use on Ikonisys' Ikoniscope fluorescence microscopy system.
Sequencing and other experiments on barcoded Plasmodium berghei mutant strains helped researchers narrow in on key metabolic pathways in the parasite's liver stage.
The company said it intends to use net proceeds from the offering to support development and commercialization for its DetermaVu and Razor assays.
The company signed a distribution agreement in Japan for its Idylla products and also initiated a listing of €150 million in unsecured convertible bonds.
JP Morgan noted that it sees potential for new management to "reset the bar" and as such thinks the "worst is in the rearview for Qiagen."
The genetic testing firm is offering approximately 2.3 million shares at $11.25 per share and plans to use the funds for general corporate purposes.
The German molecular diagnostics firm is preparing for its merger with US-based OpGen, which is slated to close in the first quarter of next year.
The firm said that in a first phase of the contract it will focus on further development of its fever test that analyzes immune system gene expression patterns.
The new name better reflects its business model combining MDx testing with the drug discovery and development services business it acquired from Cancer Genetics.
The San Diego-based company said that the number of commercial samples received during the quarter grew 66 percent year over year.
The company attributed much of the increase to its work with the VA’s Million Veteran Program, which made up three quarters of its earnings in the quarter.
In a response to the UK CMA's findings that the PacBio deal would lessen competition, Illumina said it would be open to licensing some IP to Oxford Nanopore.
Under a collaboration agreement, the firms plan to put together Agilent's SLIMS laboratory information system and MGI's DNBSeq series of sequencing platforms.
This report contains a quantitative, evidence-based scoring framework to help guide the evaluation of constitutional CNVs across clinical labs.
Centogene's data repository includes rare disease patient data including clinical information, health records, and a range of -omics data.
The Seattle-based immune cell sequencing firm saw sequencing revenues grow 38 percent while development revenues rose 65 percent.
HTG terminated a companion diagnostic development deal with Qiagen in the wake of that company's discontinuation of next-generation sequencing instruments.
Exact argues that JHU has no basis to demand any royalties on sales of Cologuard because the test doesn't use any patents the university licensed to the company.
Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.
GenomeWeb reports that Veritas Genetics is suspending its US operations.
A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.